Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Hexal (rivastigmine) — Hexal AG
Rivastigmine Hexal has been authorised for dementia-related indications in the European market.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine Sandoz (rivastigmine) — Sandoz GmbH
EMA authorised rivastigmine Sandoz for dementia indications, including Alzheimer disease and Parkinson disease.
-
EMA approval · 2026-08-20EMA Authorised: Rivastigmine 1 A Pharma (rivastigmine) — 1 A Pharma GmbH
EMA authorises rivastigmine 1 A Pharma for Alzheimer's disease, dementia, and Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2026-08-13Clinical Trial Results: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation [Phase 3]
Phase 3 trial assessing the efficacy and safety of AXS-05 in agitation associated with Alzheimer’s disease and related dementias; results ha…
-
CLINICAL_TRIALS trial_result · 2026-08-07Clinical Trial Results: A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) [Phase 1]
First-in-human Phase 1 trial results for IBC-Ab002 in individuals with early Alzheimer's disease have been completed and results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-06EMA Authorised: Neuraceq (florbetaben (18F)) — Lantheus Germany GmbH
EMA authorised Neuraceq (florbetaben [18F]) for use in radionuclide imaging to support assessment of Alzheimer's disease, under Lantheus Ger…
-
CLINICAL_TRIALS trial_result · 2026-08-06Clinical Trial Results: ALIGN: Aligning Medications With What Matters Most (Demonstration) [NA]
Clinical trial results for ALIGN study demonstrating alignment of medications with patient priorities in older adults with polypharmacy and …
-
EMA approval · 2026-08-05EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH
The EMA has authorised Leqembi (lecanemab) for cognitive dysfunction and Alzheimer's disease, with Eisai GmbH as the marketing authorization…
-
CLINICAL_TRIALS trial_result · 2026-08-03Clinical Trial Results: Brain Energy for Amyloid Transformation in Alzheimer's Disease Study [NA]
Completed clinical trial evaluating brain energy approach for Alzheimer disease and mild cognitive impairment; results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia [NA]
Study results published for a wireless controller–based lighting intervention in individuals with Alzheimer's disease; completed as of 2026.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges [NA]
Completed clinical trial evaluating deprescribing strategies in patients with dementia, including caregiver and provider nudges, with result…
-
CLINICAL_TRIALS trial_result · 2026-07-27Clinical Trial Results: Community-based Brain Health Program to Address Dementia Risk [NA]
Completed clinical trial evaluating a community-based brain health program for dementia risk with results posted.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease [Phase 2]
Phase 2 trial results on nilotinib in mild to moderate Alzheimer's disease; evaluates safety, biomarkers, and clinical outcomes.
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Results: Falls: A Marker of Preclinical AD
Completed clinical trial examining falls as a marker of preclinical Alzheimer disease and reporting results.
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease [NA]
Completed clinical trial results for Brain Safe, a consumer intervention intended to reduce exposure to drugs linked to Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2026-07-14Clinical Trial Results: Brain Health in Midlife
Completed clinical trial results on brain health in midlife, with conditions including brain health, gestational hypertension, and related n…
-
EMA approval · 2026-07-08EMA Authorised: Ebixa (memantine hydrochloride) — H. Lundbeck A/S
Memantine hydrochloride (Ebixa) has been authorised for use in Alzheimer disease in the European Union.
-
CLINICAL_TRIALS trial_result · 2026-07-08Clinical Trial Results: Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells
Exploratory open-label study results evaluating a method to detect dendritic cells in probable Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Results: The Brain Health Study: A Pragmatic, Patient-Centered Trial [NA]
The Brain Health Study is a completed pragmatic, patient-centered trial investigating dementia and Alzheimer's disease, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial [Phase 1, Phase 2]
Results from a basket trial evaluating interventions across neurodegenerative diseases including amyotrophic lateral sclerosis and Alzheimer…
-
CLINICAL_TRIALS trial_result · 2026-06-29Clinical Trial Results: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation [Phase 2]
Phase 2 trial results for XPro1595 in early Alzheimer's disease with inflammatory biomarkers have been completed and results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Results: An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study [Phase 3]
Open-label long-term safety study results for AXS-05 in dementia of the Alzheimer's type (AD) showing safety observations from ADVANCE-2 and…
-
CLINICAL_TRIALS trial_result · 2026-06-16Clinical Trial Results: Combined tDCS and Cognitive Training in Alzheimer's [NA]
Study results for combined transcranial direct current stimulation (tDCS) and cognitive training in prodromal Alzheimer's disease have been …
-
CLINICAL_TRIALS trial_result · 2026-06-12Clinical Trial Results: Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype [NA]
Completed clinical trial examining physical activity, Alzheimer's disease cognition, and APOE genotype effects.
-
CLINICAL_TRIALS trial_result · 2026-06-12Clinical Trial Results: Cholinergic Health After Menopause (CHAMP) [EARLY_Phase 1]
Early Phase 1 trial results for CHAMP study investigating cholinergic health after menopause; completed with results posted.